Immunogenicity of Plasmodium falciparum circumsporozoite protein multiple antigen peptide vaccine formulated with different adjuvants

Vaccine

Volumn 16, Issue 2-3, 1998, Pages 305-312

  Le, Thong P ^a   Preston Church, L W ^a   Corradin, Giampietro ^b   Hunter, Robert L ^c   Charoenvit, Yupin ^a   Wang, Ruobing ^a   De La Vega, Patricia ^a   Sacci, John ^a,d   Ballou, W Ripley ^e   Kolodny, Nelly ^e   Kitov, Svetlana ^e   Glenn, Gregory M ^e   Richards, Roberta L ^e   Alving, Carl R ^e   Hoffman, Stephen L ^a  

^a NAVAL MEDICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

Circumsporozoite protein; Multiple antigen peptide; Plasmodium falciparum vaccine

Indexed keywords

ADJUVANT; ALUMINUM HYDROXIDE; FREUND ADJUVANT; LIPOSOME; MALARIA VACCINE; PHOSPHORYL LIPID A;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNIZATION; IMMUNOGENICITY; MALARIA; MOUSE; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; SPOROZOITE; SUBCUTANEOUS DRUG ADMINISTRATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, PROTOZOAN; APICOMPLEXA; FEMALE; MICE; MICE, INBRED BALB C; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS;

EID: 0031986113     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(97)00165-5     Document Type: Article

References (37)

1. 1 Charoenvit, Y., Mellouk, S. and Cole, C. et al. Monoclonal, but not polyclonal antibodies protect against Plasmodium yoelii sporozoites. Journal of Immunology 1991, 146, 1020-1025.
2. 2 Charoenvit, Y., Sedegah, M. and Yuan, L.F. et al. Active and passive immunization against Plasmodium yoelii sporozoites. Bulletin of the World Health Organization 1990, 68 (Suppl.), 26-32.
3. 3 Egan, J.E., Weber, J.L. and Ballou, W.R. et al. Efficacy of malaria sporozoite vaccines: Implications for human vaccine development. Science 1987, 236, 453-456.
4. 4 Potocnjak, P., Yoshida, N., Nussenzweig, R.S. and Nussenzweig, V. Monovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice against malaria infection. Journal of Experimental Medicine 1980, 151, 1504-1513.
5. 5 Zavala, F., Tam, J.P. and Barr, P.J. et al. Synthetic peptide vaccine confers protection against murine malaria. Journal of Experimental Medicine 1987, 166, 1591-1596.
6. 6 Tam, J.P., Clavijo, P., Lu, Y., Nussenzweig, V., Nussenzweig, R. and Zavala, F. Incorporation of T and B epitopes of the circumsporozoite protein in a chemically defined synthetic vaccine against malaria. Journal of Experimental Medicine 1990, 171, 299-306.
7. 7 Wang, R., Charoenvit, Y. and Corradin, G. et al. Induction of protective polyclonal antibodies by immunization with a Plasmodium yoelii circumsporozoite protein multiple antigen peptide vaccine. Journal of Immunology 1995, 154, 2784-2793.
8. 8 Charoenvit, Y., Collins, W.E. and Jones, T.R. et al. Inability of malaria vaccine to induce antibodies to a protective epitope within its sequences. Science 1991, 251, 668-671.
9. 9 Ballou, W.R., Sherwood, J.A. and Neva, F.A. et al. Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine. Lancet 1987, 1, 1277-1281.
10. 10 Herrington, D.A., Clyde, D.F. and Losonsky, G. et al. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature 1987, 328, 257-259.
11. 11 Fries, L.F., Gordon, D.M. and Schneider, I. et al. Safety, immunogenicity, and efficacy of a Plasmodium falciparum vaccine comprising of a circumsporozoite protein repeat region peptide conjugated to Pseudomonas aeruginosa toxin A. Infection and Immunity 1992, 60, 1834-1839.
12. 12 Sturchler, D., Just, M. and Berger, R. et al. Evaluation of 5.1-[NANP]19, a recombinant Plasmodium falciparum vaccine candidate, in adults. Tropical and Geographical Medicine 1992, 44, 9-14.
13. 13 Hoffman, S.L., Edelman, R. and Bryan, J.P. et al. Safety, immunogenicity, and efficacy of a malaria sporozoite vaccine administered with monophosphoryl lipid A, cell wall skeleton of mycobacteria, and squalane as adjuvant. American Journal of Tropical Medicine and Hygiene 1994, 51, (5), 603-612.
14. 14 Gordon, D.M., McGovern, T.W. and Krzych, U. et al. Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. Journal of Infectious Diseases 1995, 171, 1576-1585.
15. 15 Tam, J.P. Synthetic peptide vaccine design synthesis and properties of a high-density multiple antigen system. Proceedings of the National Academy of Science of the United States of America 1988, 85, 5409-5413.
16. 16 Munesinghe, D.Y., Clavijo, P., Calvo-Calle, M., Nussenzweig, R.S. and Nardin, E. Immunogenicity of multiple antigen peptides (MAP) containing T and B cell epitopes of the repeat region of the P. falciparum circumsporozoite protein. European Journal of Immunology 1991, 21, 3015-3020.
17. 17 Chai, S.K., Clavijo, P., Tam, J.P. and Zavala, F. Immunogenic properties of multiple antigen peptide systems containing defined T and B epitopes. Journal of Immunology 1992, 149, 2385-2390.
18. 18 Calvo-Calle, J.M., de Oliveira, G.A. and Clavijo, P. et al. Immunogenicity of multiple antigen peptides containing B and non-repeat T cell epitopes of the circumsporozoite protein of Plasmodium falciparum. Journal of Immunology 1993, 150, 1403-1412.
19. 19 Panina-Bordignon, P., Tan, A., Termijtelen, A., Demotz, S., Corradin, G. and Lanzavecchia, A. Universally immunogenic T cell epitopes: promiscuous binding to human MHC class 11 and promiscuous recognition by T cells. European Journal of Immunology 1989, 19, 2237-2242.
20. 20 Stoute, J.A., Slaoui, M. and Heppner, D.G. et al. A preliminary evaluation of a recombinant circumsporozoite protein malaria vaccine against experimental challenge with Plasmodium falciparum. New England Journal of Medicine 1997, 336, 86-91.
21. 21 Valmori, D., Romero, J.F., Men, Y., Maryanski, J.L., Romero, P. and Corradin, G. Induction of a cytotoxic T cell response by co-injection of a T helper peptide and a cytotoxic T lymphocyte peptide in incomplete Freund's adjuvant (IFA): Further enhancement by pre-injection of IFA alone. European Journal of Immunology 1994, 24, 1458-1462.
22. 22 Valmori, D., Pessi, A., Bianchi, E. and Corradin, G. Use of human universally antigenic tetanus toxin T cell epitopes as carriers for human vaccination. Journal of Immunology 1992, 149, 717-721.
23. 23 Alving, C.R., Shichijo, S., Mattaby-Baltzer, I. et al. Preparation and use of liposomes in immunological studies. In Liposome Technology, ed. G. Gregoriadis, Vol. 3, 2nd edn., CRC Press, Boca Raton, FL, 1992, p. 317.
24. 24 Wassef, N.M., Alving, C.R. and Richards, R.L. Liposomes as carriers for vaccines. Immunomethods 1994, 4, 217-222.
25. 25 Charoenvit, Y., Leef, M.L. and Yuan, L.F. et al. Characterization of Plasmodium yoelii monoclonal antibodies directed against stage-specific sporozoite antigens. Infection and Immunity 1987, 55, 604-608.
26. 26 Pacheco, N.D., Strome, P.A., Mitchell, F., Bawden, M.P. and Beaudoin, R.L. Rapid, large-scale isolation of Plasmodium berghei sporozoites from infected mosquitoes. Journal of Parasitology 1979, 65, 414-417.
27. 27 Hollingdale, M.R., Nardin, E.H., Tharavanij, S., Schwartz, A.L. and Nussenzweig, R.S. Inhibition of entry of Plasmodium falciparum and P. vivax sporozoite into cultured cells: an in vitro assay of protective antibodies. Journal of Immunology 1984, 132, 909-913.
28. 28 Mellouk, S., Berbigvier, N. and Druile, P. et al. Evaluation of an in vitro system aimed at measuring protective antibodies against sporozoites. Bulletin of the World Health Organization 1990, 68, (Suppl.), 52-59.
29. 29 Grillot, D., Michel, M. and Muller, I. et al. Immune responses to defined epitopes of the circumsporozoite protein of the murine malaria parasite Plasmodium yoelii. European Journal of Immunology 1990, 20, 1215-1221.
30. 30 Scatzo, A.A., Elliott, S.L., Cox, J., Gardner, J., Moss, D.J. and Suhrbier, A. Induction of protective cytotoxic T cells to murine cytomegalovirus by using a nonapeptide and a human-compatible adjuvant (Montanide ISA 720). Journal of Virology 1995, 69, (2), 1306-1309.
31. 31 Hunter, R.L. and Lal, A.A. Copotymer adjuvants in malaria vaccine development. American Journal of Tropical Medicine and Hygiene 1994, 50, (Suppl 4), 52-58.
32. 32 ten Hagen, T.L.M., Sulzer, A.J., Kidd, M.R., Lal, A.A. and Hunter, R.L. Role of adjuvants in the modulation of antibody isotype, specificity, and induction of protection by whole blood-stage Plasmodium yoelii vaccines. Journal of Immunology 1993, 151, 7077-7085.
33. 33 Hunter, R.L. Kidd, M.R., Olsen, M.R., Patterson, P.S. and Lal, A.A. Induction of long-lasting immunity to Plasmodium yoelii malaria with whole blood-stage antigens and copolymer adjuvants. Journal of Immunology 1995, 154, 1762-1769.
34. 34 Bennett, B., Check, I.J., Olsen, M.R. and Hunter, R.L. A comparison of commercially available adjuvants for use in research. Journal of Immunological Methods 1992, 153, 31-40.
35. 35 Rickman, L.S., Gordon, D.M. and Wistar, R. et al. Use of adjuvant containing mycobacterial cell-wall skeleton, monophosphoryl Lipid A, and squalane in malaria circumsporozoite protein vaccine. Lancet 1991, 337, 998-1001.
36. 36 Fries, L.F., Gordon, D.M. and Richards, R.L. et al. Liposomal malaria vaccines in humans: a safe and potent adjuvant strategy. Proceedings of the National Academy of Sciences of the United States of America 1992, 89, 358-362.
37. 37 Alving, C.R., Koulchin, V., Glenn, G.M. and Rao, M. Liposomes as carriers of peptide antigen: Induction of antibodies and cytotoxic T lymphocytes to conjugated and unconjugated peptides. Immunological Reviews 1995, 145, 5-31.